Thursday, 18 Jan 2018

You are here

FDA Requests Removal of OPANA-ER from the Market

The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.

A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.

Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.  

The drug was approved in 2006, but attempts by the manufacturer in 2012 to make it harder to tamper with, lead some to either inject or snort the drug for immediate effects. This method of delivery also lead to outbreaks of HIV and hepatitis C and thrombotic microangiopathy. 

This action follows the approval of the opiods that possess greater abuse-deterrent properties.

Should Endo not voluntarily withdraw the product, it is presumed the FDA will take further action to remove it.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Cannibis Weakly Effective in Neuropathic Pain

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

However, there was little evidence that cannabis can alleviate pain associated with multiple sclerosis, cancer, or rheumatic conditions.  

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.

Fibromyalgia Diagnosed by Two Simple Tests

Researchers from the Oregon Health Science Center have reported that fibromyalgia can be distinguished from chronic pain by primary care providers (PCPs) who employ two simple screening tests: BP cuff-evoked pain and a single patient question, and pain induced by pinching the Achilles tendon. 

Opioid Crisis Costs US $500 Billion

Reuters reports that the opioid crisis has cost the United States as much as $504 billion in 2015,  based on a White House economists report released this week. The White House Council of Economic Advisers (CEA) said the toll from the opioid crisis represented 2.8% of gross domestic product that year.

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.